Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
Charles River Laboratories First Quarter 2026 Results were officially released, showcasing a company in the midst of a significant strategic transformation. The Wilmington-based contract research [Read More…]
Gilead Sciences reports a strong Q1 2026 with $6.96 billion in revenue, driven by its industry-leading HIV portfolio and the rapid uptake of Yeztugo, despite acquisition-related guidance adjustments.
Released in May 2026, the Novo Nordisk Q1 2026 report showcases a complex but optimistic financial picture, highlighting a massive revenue beat fueled by the record-breaking U.S. launch of the Wegovy pill, prompting the pharmaceutical giant to raise its full-year guidance.
Pfizer has reported its first-quarter 2026 earnings, exceeding market expectations with $14.5 billion in revenue. The company reaffirmed its full-year guidance, bolstered by a 22% operational growth in launched and acquired products.
Amgen has reported a robust start to the year, with its Q1 2026 financial results exceeding analyst estimates. Total revenue climbed to $8.6 billion, driven by double-digit growth across 16 key brands and a promising expansion of the MariTide obesity program.
Eli Lilly and Company’s Q1 2026 results showcased a 56% revenue surge to $19.8 billion, driven by unparalleled demand for its incretin portfolio and breakthrough oncology treatments.
Biogen reported a solid start to the year with its Q1 2026 results, featuring 12% growth in new products and a major move to acquire Apellis Pharmaceuticals to bolster its rare disease and nephrology portfolios.
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
